However, NRAS-mutant melanoma, a subtype comprising 15–25% of melanomas, remains refractory to most current treatments and is associated with a poorer prognosis compared to BRAF-mutant or wild-type variants [5,6]. This evidence concerns the gene NRAS and melanoma.